A study has used a proteomic method to uncover why some melanoma tumours do not respond to immunotherapy, which could improve treatments.
List view / Grid view
Study in the U.S. demonstrates successful treatment of advanced melanoma and metastatic cancer using a new bacteria-like agent combined with an immunotherapy drug.
Scientists have investigated the mechanisms by which the lymphatic endothelial cells modulate metastasis in melanoma, providing new targets for therapy development.
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.1